Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 222 | — | — | Sep 19, 2022 | Sep 30, 2027 | May 15, 2026 | 64 | United States, Australia +11 |
Number of participants with adverse events
Number of participants with dose limiting toxicities
| Arm | Type | Description |
|---|---|---|
| RMC-6291 | EXPERIMENTAL | Dose Escalation and Dose Expansion |
| Name | Type | Description |
|---|---|---|
| RMC-6291 | DRUG | Oral tablet once or twice a day |
Inclusion Criteria: * Subject must be ≥18 years of age. * Subject must have pathologically documented, locally advanced or metastatic KRASG12C-mutated solid tumor malignancy (not amenable to curative surgery) that has previously been treated with standard-of-care therapies for respective tumor type...